Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Fidaxomicin

Fidaxomicin

Macrocyclic antibiotic (PO)

C diffNarrow spectrum

Indication

Initial CDI β€’ recurrent CDI prevention strategies

At a glance

INDICATIONS (CORE USE)

**C. diff infection** β€” narrower spectrum than vanco β†’ **lower recurrence** in trials vs vanco some populations; expensive.

ADULT DOSE (STANDARD)

200 mg PO BID Γ— 10 days standard

MAX DOSE

200 mg BID

Route

PO

PEDIATRIC DOSE

Pediatric dosing exists β€” weight-based per label

Do not miss

Must-not-miss safety points

Major warning

- Does not treat systemic infection β€” CDI only - Hypersensitivity rare - Cost/access β€” formulary restrictions common

Indications

USE IF: CDI when guideline recommends fidaxomicin (first episode high-risk recurrence, recurrent CDI strategies). AVOID IF: Non-CDI infection.

Primary

  • Clostridioides difficile infection (non-fulminant oral therapy)

Secondary

  • Recurrent CDI prevention protocols β€” ID/gastroenterology

Dosing

STANDARD (ADULT PO)

200 mg PO BID Γ— 10d

ADULT DOSE

200 mg BID; extended pulsed regimens specialist only

PEDIATRIC DOSE

Per pediatric label.

MAX DOSE

200 mg BID

Practical Note

May take with or without food.

Warnings

Clinical warnings

  • Vomiting limits completion β€” consider vancomycin liquid

Adverse effects

  • nausea
  • vomiting
  • abd pain

Contraindications

  • Hypersensitivity to fidaxomicin

Drug interactions

  • P-gp inhibitors may ↑ levels β€” clinical relevance usually low

Special populations

Pediatrics

Pediatric dosing exists β€” weight-based per label

Pregnancy

Limited human data β€” risk-benefit

Lactation

unknown.

Renal impairment

No adjustment. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + institutional pharmacy nomogram):** - **CrCl β‰₯50** β†’ standard - **CrCl 10–50** β†’ minimal adjustment per label - **CrCl <10** β†’ severe combined organ failure per label

Hepatic impairment

Severe hepatic impairment limited data.

Elderly

Frailty β€” swallow tablet or suspension availability.

Administration

PO whole tablet or oral suspension preparation.

Monitoring

  • Monitor: - Recurrence **day 7–28** β†’ second episode β†’ **ID** pathway - Recurrence day 7–28 watch - Fulminant features β†’ surgery consult
  • Recheck: - 48–72 h β†’ stool frequency / abdominal exam β†’ no improvement β†’ reassess diagnosis / alternate therapy - Clinical diarrhea 48–72h - No clinical improvement at 48–72h β†’ reassess diagnosis, resistance, source control, and drug interactions - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

**Life-threatening (first):** **anaphylaxis** (rare). **Secondary:** expected mild GI.

Immediate Actions

Stop if concern β†’ supportive; anaphylaxis β†’ epinephrine if indicated

Antidote

No specific antidote; treat complications (e.g. anaphylaxis β†’ epinephrine per ACLS)

Decontamination

N/A

Escalation

Severe anaphylaxis β†’ ED/**ICU**

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**CDI-only** drug. **Recurrence advantage** vs vanco in selected trials β€” use when access + guideline align. Not for colonic CDI via IV (no absorption).

Clinical pearls

Stewardship: stop unnecessary PPI/antibiotics driving CDI. Bezlotoxumab for recurrence prevention β€” separate decision. Fecal transplant recurrent β€” ID/GI. *Stewardship (all antimicrobials):* Empiric choice β†’ syndrome severity + **local antibiogram**; shortest effective course.

Stewardship & safety

  • CDI only
  • Recurrence strategy
  • Cost/access

Pharmacokinetics

Minimal systemic absorption β€” gut lumen active.

Mechanism of action

Inhibits bacterial RNA polymerase β€” narrow spectrum anaerobic gram-positive.

Common brand names

Global data (no country-specific data available)

Saudi Arabia

(placeholder β€” verify local formulary)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Empiric choice β†’ tie to syndrome, severity, and local antibiogram β€” not habit.
  • IV β†’ PO step-down when oral bioavailability and susceptibility allow.
  • Do not use antibiotics for uncomplicated viral illness β€” stewardship.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling

Do not miss

  • Uncomplicated viral URI/bronchitis β†’ antibiotics rarely indicated
  • Narrow or stop when susceptibilities + clinical stability allow
  • Billing expensive drug for non-CDI indication.
  • Fulminant CDI needs surgery/vanco high-dose protocols β€” not oral fidaxo alone.
  • CDI only
  • Recurrence strategy
  • Cost/access